Golden Meditech Proposes Open Offer to Eligible Shareholders to Subscribe One Offer Share for Every Two Shares Held And to Acquire Outstanding Ordinary Shares of China Cord Blood Corporation

HONG KONG, April 29, 2015 /PRNewswire/ -- Golden Meditech Holdings Limited ("Golden Meditech," together with its subsidiaries collectively as the "Group") (801.HK; 910801.TW), a leading integrated healthcare enterprise in China proposes a share issue to qualifying shareholders by way of an open offer on the basis of one offer share for every two shares held at the subscription price of HK$1.40 per offer share.  The qualifying shareholders also have the right to apply for excess offer shares. 

On 27 April 2015, Golden Meditech issued a non-binding proposal letter to the board of directors of China Cord Blood Corporation ("CO"), a non-wholly owned subsidiary of Golden Meditech and a company listed on the New York Stock Exchange, to acquire all the ordinary shares of CO which are not already directly or indirectly owned by Golden Meditech. Golden Meditech is prepared to offer US$6.40 in cash per share for each outstanding ordinary share of CO that is not already directly or indirectly owned by Golden Meditech.  In addition, Golden Meditech also intends to acquire all the 7% senior convertible notes of CO pursuant to the terms and conditions of such convertible notes.

For more information about the open offer and acquisition proposal, please refer to the announcement published by the Company on 29 April 2015 under the link below, and any update announcement published by the Company from time to time.

http://www.irasia.com/listco/hk/goldenmeditech/announcement/a140793-egmii.pdf  

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China's leading integrated-healthcare enterprise.  Golden Meditech is a first-mover in China, having established dominant positions in medical devices, and cord blood storage and hospital management businesses of the healthcare services markets, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

SOURCE Golden Meditech Holdings Limited

Related Links

http://www.goldenmeditech.com